Clinical compliance with an oral uracil/tegafur (UFT) plus leucovorin (LV) regimen as adjuvant chemotherapy in Japanese colorectal cancer patients

Meguro, Makoto; Furuhata, Tomohisa; Okita, Kenji; Nishidate, Toshihiko; Ishiyama, Gentaro; Iwayama, Yuji; Kimura, Yasutoshi; Mizuguchi, Toru; Hirata, Koichi

doi:10.1007/s10147-009-0888-1

Cited by 7 publications

(8 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tegafur is the 5-FU prodrug converted to 5-FU in the liver. LV is used to modulate 5-FU biochemically, and has been widely adopted for the treatment of advanced colorectal cancer [8,15]. The 5-week cycles of chemotherapy consisted of 4 weeks of oral UFT/LV, followed by 1 week of rest, and were repeated for ≥6 months.…”

Section: Methodsmentioning

confidence: 99%

“…The National Surgical Adjuvant Breast and Bowel Project (NSABP) reported the results of a surgical adjuvant clinical trial (protocol C-03) that indicated significant extension of DSF and OS in stage II and III colon cancer patients who received fluorouracil (5-FU) plus leucovorin (LV) compared with patients who received semustine, vincristine, and 5-FU (protocol C-04) [3-5]. Furthermore, the NSABP protocol C-06 demonstrated that oral uracil and tegafur (UFT) plus LV (UFT/LV) were associated with DSF and OS rates similar to those obtained with a regimen of intravenous weekly bolus 5-FU plus LV (5-year DFS 67.0% versus 68.2%, 5-year OS 78.5% versus 78.7%) [6-8]. 5-FU significantly improves DFS and OS rates over surgery alone, with relative risk reductions of 30% and 26%, respectively [9].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Inferior oncological prognosis of surgery without oral chemotherapy for stage III colon cancer in clinical settings

et al. 2014

View full text Add to dashboard Cite

BackgroundCancer patients not admissible for adjuvant chemotherapy are generally at high risk of considerably inferior prognosis. The aim of this retrospective study was to evaluate poorer survival without administration of oral adjuvant chemotherapy of stage III colon cancer patients in clinical settings.MethodsBetween April 2007 and September 2011, 259 patients with stage III colon cancer who underwent curative surgery were retrospectively assigned to the adjuvant chemotherapy group of 171 patients (66%) and the surgery alone group of 88 patients. Oral fluorouracil (5-FU) derivatives used in adjuvant chemotherapy, such as oral uracil and tegafur plus leucovorin (UFT/LV) or capecitabine, were the most commonly used.ResultsThe 3-year relapse-free survival (RFS) rates were 74.9% for all cases, 58.3% for the surgery alone group, and 83.4% for the adjuvant chemotherapy group (P = 0.0001). The chemotherapy group was associated with a dramatic improvement in survival for stage IIIB (surgery alone 57.7% versus adjuvant chemotherapy 83.9%; P = 0.0001) and stage IIIC (surgery alone 18.2% versus adjuvant chemotherapy 57.3%; P = 0.006) patients. There was a significant difference in the overall recurrence rate between groups (surgery alone 35.2% versus adjuvant chemotherapy 18.1%; P = 0.002). Multivariate analysis identified adjuvant therapy as an independent predictive factor of reduced recurrence (hazard ratio (HR): 3.231; P = 0.004) and improved RFS (HR: 2.653; P = 0.001).ConclusionIn clinical settings, adjuvant therapy was the only significant prognostic factor of survival. Since many patients prefer not to receive chemotherapy, it is critical to inform stage III colon cancer patients that chemotherapy raises their chances of survival by three-fold compared with curative surgery alone.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Inferior oncological prognosis of surgery without oral chemotherapy for stage III colon cancer in clinical settings

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Grade 3 or above diarrhea developed in 29% of patients and vomiting in 5%. Meguro et al reported that the consecutive UFT/LV regimen could be completed in 82.5% of patients without any toxicity of grade 3 or above (8). The authors reported, however, that the most frequent non-hematologic toxicities were appetite loss (50%) and fatigue (60%) and that diarrhea and nausea/vomiting developed in 30 and 40% of patients, respectively.…”

Section: Discussionmentioning

confidence: 99%

Feasibility of 5-days-on/2-days-off UFT/leucovorin in post-operative long-term adjuvant chemotherapy for colorectal cancer

Tokunaga

Sasaki

2012

Oncol Lett

View full text Add to dashboard Cite

Abstract.Previous clinical studies have shown that the oral uracil/tegafur (UFT)/leucovorin (LV) regimen, in which the drugs are taken for 28 consecutive days every 35 days, is equivalent to an infusional 5-fluorouracil (5-FU)/LV regimen for the treatment of colorectal cancer. A 5-days-on/2-daysoff schedule for UFT/LV has been proposed as the same schedule for UFT has been reported to be safe and have good compliance. However, few studies have been performed with regards to the feasibility of the UFT/LV regimen. The results of the 5-days-on/2-days-off schedule were compared with those of the consecutive schedule in adjuvant chemotherapy. Twenty-eight patients were treated with the 5-days-on/ 2-days-off schedule of UFT (300 mg/m 2 /day)/LV (75 mg/ body/day), and another 12 patients were treated with the consecutive schedule. In the 5-days-on/2-days-off schedule, 24 of 28 patients (86%) received all the scheduled doses. In the consecutive schedule, 10 of 12 patients (83%) received all the scheduled doses. The mean relative dose intensities for the 5-days-on/2-days-off and consecutive schedules were 0.92 and 0.87, respectively. The toxicities were milder in the 5-days-on/2-days-off schedule compared with the consecutive schedule. The disease-free survival in patients with the 5-days-on/2-days-off schedule tended (P=0.13) to be longer compared with the consecutive schedule. The results of the present study indicate that the 5-days-on/2-days-off schedule of UFT/LV may be feasible and cause no severe toxicities in long-term adjuvant chemotherapy.

show abstract

“…LV was used to modulate 5-FU biochemically, and has been widely adopted for the treatment of advanced colorectal cancer. 8,14 Chemotherapy was given in 5-week cycles consisting of 4 weeks of oral UFT/LV and 1 week of rest. The cycles were repeated at least 5 times.…”

Section: Adjuvant Chemotherapy Regimensmentioning

confidence: 99%

“…[3][4][5] NSABP protocol C-06 demonstrated that an oral regimen of uracil and tegafur (UFT) plus leucovorin (LV) was associated with DFS and OS similar to those obtained with a regimen of a weekly intravenous bolus of 5-FU/LV (5-year DFS 67.0% vs. 68.2%, 5-year OS 78.5% vs. 78.7%). [6][7][8] Pooling data from more than 3000 patients showed that adjuvant 5-FU significantly improves DFS and OS over surgery alone, with relative risk reductions of 30% and 26%, respectively. 9 The efficacy and tolerability of oral capecitabine (CAPE) was compared with 5-FU/LV by intravenous bolus for patients with stage III colon cancer in the adjuvant colon cancer therapy trial.…”

Section: Introductionmentioning

confidence: 99%

Oncologic Outcomes of Oral Adjuvant Chemotherapy Regimens in Stage III Colon Cancer: Tegafur–Uracil Plus Leucovorin Versus Capecitabine

Tashiro

Yamaguchi

Ishii

et al. 2017

Clinical Colorectal Cancer

View full text Add to dashboard Cite

show abstract

Clinical compliance with an oral uracil/tegafur (UFT) plus leucovorin (LV) regimen as adjuvant chemotherapy in Japanese colorectal cancer patients

Abstract: The regimen of oral UFT plus LV produced only low-grade toxicity and was convenient for outpatients. It appears that the initial UFT dose might be associated with the development of toxicity in the oral UFT plus LV regimen.

Cited by 7 publications

References 11 publications

Inferior oncological prognosis of surgery without oral chemotherapy for stage III colon cancer in clinical settings

Inferior oncological prognosis of surgery without oral chemotherapy for stage III colon cancer in clinical settings

Feasibility of 5-days-on/2-days-off UFT/leucovorin in post-operative long-term adjuvant chemotherapy for colorectal cancer

Oncologic Outcomes of Oral Adjuvant Chemotherapy Regimens in Stage III Colon Cancer: Tegafur–Uracil Plus Leucovorin Versus Capecitabine

Contact Info

Product

Resources

About